drugset / Trial / NCT04925284
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
RandomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2025-03-10
- Completion
- 2025-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | XB002 | Unknown | — | Intravenous |